BioTime (BTX) Tops Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
May 9, 2019 4:05 PM EDTPositive OpRegen® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd.
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, reported financial and operating results for the first quarter ended March 31,... More
